

NIH Workshop: Developing Meaningful Endpoints for Pain Clinical Trials

PAIN CLINICAL ENDPOINTS- BIOMARKERS



Petra Schweinhardt MD PhD
Balgrist University Hospital
University of Zurich
Zurich
Switzerland

IMMPACT Biomarker assessment:

- Neuroimaging
- Sensory Testing
- Skin Biopsies

Brain-based biomarkers

For pain as the problem (=disease): obvious option - sensation of pain is a brain function



Brain-based biomarkers

For pain as the problem (=disease): obvious option - sensation of pain is a brain function

As diagnostic biomarker (detection of pain)?

Problematic (e.g. Davis et al. 2017; Nature Reviews Neurology)

Potential benefit: more sensitive – e.g. treatment responsiveness detected earlier (Duff et al. Science Translational Medicine 2015)

Brain-based biomarkers


For pain as the problem (=disease): obvious option - sensation of pain is a brain function

As diagnostic biomarker (detection of pain)?

Problematic (e.g. Davis et al. 2017; Nature Reviews Neurology)

Potential benefit: more sensitive – e.g. treatment responsiveness detected earlier (Duff et al. Science Translational Medicine 2015)

As 'mechanistic' biomarker?



Pain = 7




Pain = 7



**Different
endophenotypes**

Brain-based biomarkers

Endophenotypes as predictive/prognostic biomarker?



Brain-based biomarkers – resting state networks

Default mode network changes: 'chronic pain seems to reorganize the dynamics of the DMN and as such reflect the maladaptive physiology of different types of chronic pain'.

	DMN-insula connectivity up	DMN-some other non-DMN region connectivity up
n=20 (505 patients)	n=10	n=9

Brain-based biomarkers – resting state networks

Default mode network changes: 'chronic pain seems to reorganize the dynamics of the DMN and as such reflect the maladaptive physiology of different types of chronic pain'.

	DMN-insula connectivity up	DMN-some other non-DMN region connectivity up	Pain at time of study visit? Yes	Pain at time of study visit? Not reported
n=20 (505 patients)	n=10	n=9	n=10	n=5

Brain-based biomarkers – resting state networks

Fibromyalgia patients: chronic widespread pain for at least 1 year with an average daily intensity of at least 4/10.

	Patients (n=27)		Controls (n=16)	
	Patients (n=27)	Controls (n=27)	Patients (n=16)	Controls (n=16)
Age (yrs)	42	42	49	49
Pain duration (yrs)	11	n/a	12	n/a
Anxiety symptoms (HADS)	8	4	10	5
Depression symptoms (HADS)	5	2	5	2



Brain-based biomarkers – resting state networks

Fibromyalgia patients: chronic widespread pain for at least 1 year with an average daily intensity of at least 4/10.

	Scanner pain-free cohort		Scanner pain cohort	
	Patients (n=27)	Controls (n=27)	Patients (n=16)	Controls (n=16)
Age (yrs)	42	42	49	49
Pain duration (yrs)	11	n/a	12	n/a
Anxiety symptoms (HADS)	8	4	10	5
Depression symptoms (HADS)	5	2	5	2
Pain at the time of scan (/10)	0	0	4.4	0.05





Brain-based biomarkers – resting state networks

Scanner pain cohort




Brain-based biomarkers – resting state networks




Scanner pain cohort



Brain-based biomarkers – resting state networks



Brain-based biomarkers – resting state networks



Brain-based biomarkers


Pain as a symptom




Brain-based biomarkers




Biomarkers








Heat pain ratings



Mechanical pain threshold






Untersucher: _____

Name Pat.: _____

Pat. ID: CRPP-019




Intensität


Kein Schmerz 0 1 2 3 4 5 6 7 8 9 10 Stärkste vorstellbare Schmerzen

x = schmerzhafteste Stelle

Kommentare

Quantitative Sensory Testing profiles






Untersucher: _____

Name Pat.: _____


Pat. ID: CRPP-019




Intensität
 Kein Schmerz 0 1 2 3 4 5 6 7 8 9 10 Stärkste vorstellbare Schmerzen
 x = schmerzhafteste Stelle

Kommentare

Quantitative Sensory Testing profiles



Take home messages

- The biomarker to choose / aim to develop depends very much on the purpose
 - A suitable biomarker for pain might depend on the underlying condition, even in the instance of chronic pain
 - It is difficult but not hopeless!
-
- 



**Integrative Spinal
Research**

**Department of
Chiropractic
Medicine**


**University Hospital
Balgrist Zurich**



SWISS NATIONAL SCIENCE FOUNDATION



**University of
Zurich^{UZH}**



**Mirjam Baechler
DC**



**Susanne Becker
PhD**



**Simon Carisch MSc
Research assistant**



**Lucas Connolly
PhD candidate**



**Melissa Flury
MSc trainee**



**Shaili Gour
PhD
candidate**



**Alexander Guekos
PhD candidate**



**Melanie Häusler
Dr. med. chiro.**



**Leonie Hofstetter
Dr. med. chiro.**



**César
Hincapié DC
PhD**



**Anke Langenfeld
PT PhD**



**Michael L Meier
PhD**



**Malin Mühlemann
Dr. med. chiro.**



**Luana Nyirö
M. chiro. med.
PhD candidate**



**Gil Sharvit
PhD**



**Laura Sirucek
PhD candidate**



**Jaap
Swanenburg PT
PhD**



**Lucas Tauschek BSc
PT
Research coordinator**



**Brigitte
Wirth PT
PhD**